The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in Villous Atrophy as Measured by Villous Height to Crypt Depth Ratio (Vh:Cd)
Timeframe: Baseline, Week 8
Number of Participants With at Least One Treatment-Emergent Adverse Event
Timeframe: Up to Week 28
Number of Participants With at Least One Treatment-Emergent Serious Adverse Event
Timeframe: Up to Week 28
Number of Participants With at Least One Protocol-Defined Adverse Event of Special Interest (PDAESI)
Timeframe: Up to Week 28
Number of Participants Who Discontinued From the Study Due to an Adverse Event
Timeframe: Up to Week 28